Skip to content

Boston Scientific BSX Derivatives, gross, liabilities

Derivatives, gross, liabilities at other companies

Abbott logo
AbbottABT
Medtronic logo
MedtronicMDT

Other financials

Income statement

See full
Revenue$5.2B+11.6%
Gross profit$3.6B+12.6%
Operating income$1.1B+19.5%
Net income$1.3B+99.3%
EPS (diluted)$0.90+100%

Balance sheet

See full
Cash & equivalents$850.0M+146%
Total equity$25.9B+16.4%
Total assets$44.4B+10.5%

Cash flow

See full
Operating cash flow$348.0M-35.7%
CapEx$177.0M-5.4%
Free cash flow$171.0M-51.7%

Valuation

See full
Market cap$66.81B-37.5%
P/E18.8×-34.0×
P/S3.2×-2.8×

Profitability

See full
Gross margin69.2%+0.5pp
Operating margin18.4%+2.2pp
Net margin17.3%+5.7pp

Returns & leverage

See full
Return on equity14.8%+5.2pp
Debt / equity-0.5×
Current ratio1.9×+0.4×

Where this comes from

Reported directly by Boston Scientific in its filing.

Tagged under the XBRL concept us-gaap:DerivativeFairValueOfDerivativeLiability.

The official record: Boston Scientific’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Boston Scientific's derivatives, gross, liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Boston Scientific's derivatives, gross, liabilities?
Boston Scientific (BSX) reported derivatives, gross, liabilities of $1.23B in Q1 2026.
How has Boston Scientific's derivatives, gross, liabilities changed year-over-year?
Boston Scientific's derivatives, gross, liabilities increased by 17.5% year-over-year, from $1.05B to $1.23B.
What is the long-term trend for Boston Scientific's derivatives, gross, liabilities?
Over 5 years (2020 to 2025), Boston Scientific's derivatives, gross, liabilities has grown at a 0.7% compound annual growth rate (CAGR), from $1.26B to $1.31B.